Read by QxMD icon Read

Multiple Sclerosis Health Quality

Justine Orr, Charles N Bernstein, Lesley A Graff, Scott B Patten, James M Bolton, Jitender Sareen, James J Marriott, John D Fisk, Ruth Ann Marrie
BACKGROUND: Within the multiple sclerosis (MS) population, depression and anxiety are highly prevalent comorbidities that are associated with adverse outcomes such as diminished quality of life and disability progression. In the general population, many people who do not meet formal diagnostic criteria for depression or anxiety disorders still identify a need for mental health care. Limited data are available regarding the perceived need for mental health care among persons with MS. OBJECTIVE: We aimed to determine factors associated with a perceived need for mental health care in the MS population...
July 29, 2018: Multiple Sclerosis and related Disorders
Hanna Gyllensten, Andrius Kavaliunas, Kristina Alexanderson, Jan Hillert, Petter Tinghög, Emilie Friberg
Background: Population-based estimates of costs of illness and health-related quality of life, by disability levels among people with multiple sclerosis, are lacking. Objectives: To estimate the annual costs of illness and health-related quality of life, by disability levels, among multiple sclerosis patients, 21-64 years of age. Methods: Microdata from Swedish nationwide registers were linked to estimate the prevalence-based costs of illness in 2013, including direct costs (prescription drug use and specialised healthcare) and indirect costs (calculated using sick leave and disability pension), and health-related quality of life (estimated from the EQ-5D)...
July 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Ali Dehghani, Abdolkhalegh Keshavarzi
BACKGROUND: Assessment of health literacy among patients with multiple sclerosis can be used in education planning, disease management, compliance, and quality of life. In addition, health literacy can be assessed using a standard questionnaire based on the social and cultural context more accurately. This study aimed to develop and validate a questionnaire for the assessment of health literacy in patients with multiple sclerosis. METHODS: This is an exploratory sequential mixed method research which was conducted in three sections...
July 26, 2018: Multiple Sclerosis and related Disorders
Christian Cordano, Annalisa Armezzani, Jacopo Veroni, Matteo Pardini, Davide Sassos, Maria Teresa Infante, Andrea Tacchino, Caterina Lapucci, Maria Cellerino, Valentina Calabrò, Luigi Ciullo, Bardia Nourbakhsh
Context: Research on the effect of osteopathic manipulative therapy (OMTh; manipulative care provided by foreign-trained osteopaths) on chronic symptoms of multiple sclerosis (MS) is lacking. Objective: To evaluate the effect of OMTh on chronic symptoms of MS. Methods: Patients with MS who were evaluated at the neurology clinic at Genoa University in Italy were recruited for this study. Participants received 5 forty-minute MS health education sessions (control group) or 5 OMTh sessions (OMTh group)...
August 1, 2018: Journal of the American Osteopathic Association
Laura Barin, Anke Salmen, Giulio Disanto, Haris Babačić, Pasquale Calabrese, Andrew Chan, Christian P Kamm, Jürg Kesselring, Jens Kuhle, Claudio Gobbi, Caroline Pot, Milo A Puhan, Viktor von Wyl
BACKGROUND: MS symptoms affect many functional domains. Knowing the specific impact of symptoms on health-related quality of life (HRQoL) is vital for successful disease and symptom management in MS. We aimed at investigating how specific MS symptoms contribute to the disease burden in individuals and from a population perspective. METHODS: We included 855 Swiss Multiple Sclerosis Registry participants with a relapsing-remitting form (RRMS) or a progressive form (PMS)...
July 21, 2018: Multiple Sclerosis and related Disorders
Isaac Rahimian Boogar, Siavash Talepasand, Mohammad Jabari
Introduction: Relapsing-remitting multiple sclerosis is a debilitating neurological disease accompanied with adverse consequences for quality of life. The purpose of this study was to investigate the role of relapsing-remitting multiple sclerosis on psychological, disease-related, socioeconomic, and demographic determinants of health-related quality of life of patients. Methods: In this cross-sectional descriptive study, 193 patients with relapsing-remitting multiple sclerosis were selected by compliance sampling method among the patients who attended the Iranian Multiple Sclerosis Association in Tehran from March 2014 to July 2014; and they completed the Multiple Sclerosis Quality of Life Questionnaire, the Depression Anxiety and Stress Scales, and the Socio-demographical Questionnaire...
March 2018: Noro Psikiyatri Arsivi
Sasitorn Siritho, Montarat Thavorncharoensap, Chalakorn Chanatittarat, Pakamas Pasogpakdee, Metha Apiwattanakul, Naraporn Prayoonwiwat, Siwaporn Chankrachang, Arthorn Riewpaiboon, Usa Chaikledkaew
BACKGROUND: Multiple sclerosis (MS) and neuromyelitis optica spectrum (NMOSD) cause several symptoms that negatively impact on patient's quality of life. No study has ever conducted to examine the quality of life of MS and NMOSD patients, especially in terms of health utility, among the non-western population. This study aims to examine health utility among MS and NMOSD patients in Thailand. METHODS: A multicenter cross-sectional study including 104 MS and 186 NMOSD patients was conducted...
July 4, 2018: Multiple Sclerosis and related Disorders
Karen Schreiber, Matthias Kant, Claudia Pfleger, Henrik Boye Jensen, Ole Oesterberg, Anne Rieper Hald, Frederik K Nielsen, Sune Rubak
Purpose: Treatment adherence is a prerequisite for treatment success and therefore an important consideration to assure that therapeutic goals are achieved both from a patient point of view and for optimal health care resource utilization. Published data on treatment adherence with fingolimod (Gilenya® ) are limited. Therefore, this study investigated treatment adherence in patients with relapsing-remitting multiple sclerosis (RRMS) treated with fingolimod in Denmark. Patients and methods: This was a 24-month, multicenter, open-label study, investigating treatment adherence, satisfaction, motivation, and health-related quality of life (QoL) in RRMS patients treated with fingolimod...
2018: Patient Preference and Adherence
Eva Hyncicova, Adam Kalina, Martin Vyhnalek, Tomas Nikolai, Lukas Martinkovic, Jiri Lisy, Jakub Hort, Eva Meluzinova, Jan Laczó
BACKGROUND: Neuropsychiatric symptoms and reduced health-related quality of life (HRQoL) are frequent in multiple sclerosis, where are associated with structural brain changes, but have been less studied in clinically isolated syndrome (CIS). OBJECTIVE: To characterize HRQoL, neuropsychiatric symptoms (depressive symptoms, anxiety, apathy and fatigue), their interrelations and associations with structural brain changes in CIS. METHODS: Patients with CIS (n = 67) and demographically matched healthy controls (n = 46) underwent neurological and psychological examinations including assessment of HRQoL, neuropsychiatric symptoms and cognitive functioning, and MRI brain scan with global, regional and lesion load volume measurement...
2018: PloS One
Derrick Robertson, Angela Aungst, Ryan Collier, Jhulianna Vivar, Natalie Moreo, Lise Casady, Tuan Vu
Purpose: Sexual dysfunction is a common but often overlooked secondary symptom of multiple sclerosis (MS) and can be associated with a decreased health-related quality of life (HRQoL). Natalizumab is a disease-modifying therapy approved for the treatment of relapsing forms of MS. In addition to its efficacy, those using natalizumab have shown improvement in HRQoL parameters, including fatigue and cognition. The idea that improvement in fatigue may also correlate with improvement in sexual dysfunction is the impetus for this study...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
Núria Sola-Valls, Yolanda Blanco, María Sepúlveda, Sara Llufriu, Elena H Martínez-Lapiscina, Irati Zubizarreta, Irene Pulido-Valdeolivas, Carmen Montejo, Pablo Villoslada, Albert Saiz
Background: Gait impairment is common in multiple sclerosis (MS) and negatively impacts patients' health-related quality of life (HRQoL). Prolonged-release fampridine (PR-fam) improves walking speed, but it is unclear which walking measures are the most suitable for identifying treatment response. Our aim was to assess the effect of PR-fam and the outcome measures that best identify short- and long-term clinically meaningful response. Methods: We conducted a prospective study in 32 MS patients treated with PR-fam for a year...
2018: Therapeutic Advances in Neurological Disorders
Musa Muhtaroglu, Senem Ertugrul Mut, Ferda Selcuk, Mehtap Malkoc
The aim of this study was to evaluate respiratory muscle strength, respiratory functions and quality of life in multiple sclerosis (MS) patients and compare the results with the healthy volunteers. The study included a group of 24 patients diagnosed with MS (16 women, 8 men) with an EDSS score of ≤ 5, who were without clinical respiratory impairment. MS patients were compared with the healthy volunteer group (16 women, 8 men). Respiratory muscle strength and respiratory functions were evaluated with specific devices...
July 4, 2018: Acta Neurologica Belgica
Luis Hernandez, Malinda O'Donnell, Maarten Postma
BACKGROUND: Numerous cost-effectiveness analyses (CEAs) of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) have been published in the last three decades. Literature reviews of the modeling methods and results from these CEAs have also been published. The last literature review that focused on modeling methods, without country or time horizon in the inclusion criteria, included studies published up to 2012. Since then, new DMTs have become available, and new models and data sources have been used to assess their cost effectiveness...
July 3, 2018: PharmacoEconomics
Richard D Zorowitz, David N Alexander, Andrea E Formella, Fred Ledon, Charles Davis, Joao Siffert
BACKGROUND: Dextromethorphan (DM) / quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based on efficacy and safety trials in patients with PBA caused by amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke, dementia, or traumatic brain injury. OBJECTIVE: To report results from the stroke cohort of PRISM II, including the Stroke Impact Scale (SIS). DESIGN: Open-label trial evaluating twice-daily DM/Q over 90 days...
June 30, 2018: PM & R: the Journal of Injury, Function, and Rehabilitation
Jure Tornic, Jalesh N Panicker
PURPOSE OF REVIEW: Multiple sclerosis (MS) is the most frequent neuroinflammatory disease of the central nervous system and is commonly associated with lower urinary tract (LUT) dysfunction. As a consequence, health-related quality of life is often impaired and the upper urinary tract might be at risk for damage. The aim of this review is to give an overview of current treatment options for LUT dysfunction in patients with MS. RECENT FINDINGS: The treatment is tailored to the type of dysfunction-storage or voiding dysfunction-beginning with conservative treatment options and ending with invasive therapies and surgery...
June 28, 2018: Current Neurology and Neuroscience Reports
Pierre Michel, Karine Baumstarck, Anderson Loundou, Badih Ghattas, Pascal Auquier, Laurent Boyer
Background: The aim of this study was to propose an alternative approach to item response theory (IRT) in the development of computerized adaptive testing (CAT) in quality of life (QoL) for patients with multiple sclerosis (MS). This approach relied on decision regression trees (DRTs). A comparison with IRT was undertaken based on precision and validity properties. Materials and methods: DRT- and IRT-based CATs were applied on items from a unidi-mensional item bank measuring QoL related to mental health in MS...
2018: Patient Preference and Adherence
Nastaran Majdinasab, Foroogh Namjoyan, Mohsen Taghizadeh, Hamid Saki
Background: Multiple sclerosis (MS) is a chronic progressive and inflammatory disease of the central nervous system that is characterized by demyelination in the central nervous system. In regard to the prevalence of diseases and enormous costs imposed on society and the health system, finding a way to stop the progression of the disease using drugs with fewer side effects seems a serious sanitation issue to the health of the international community. This study aimed to evaluate the effect of evening primrose oil (EPO) on fatigue and quality of life in patients with MS...
2018: Neuropsychiatric Disease and Treatment
Isabela Maia Diniz, Augusto Afonso Guerra, Livia Lovato Pires de Lemos, Kathiaja M Souza, Brian Godman, Marion Bennie, Björn Wettermark, Francisco de Assis Acurcio, Juliana Alvares, Eli Iola Gurgel Andrade, Mariangela Leal Cherchiglia, Vânia Eloisa de Araújo
BACKGROUND: Multiple Sclerosis (MS) is a disease that appreciably impacts on the quality of life of patients and is associated with high expenditure. MS is a chronic multifactorial disease, characterized by inflammation, demyelination and axonal loss. The Brazilian public health system provides pharmacological treatment as well as hospital and outpatient care for patients with relapsing-remitting and secondary progressive multiple sclerosis. However, we are not aware of any previous publications assessing total direct medical costs in patients with a long follow-up within the Brazilian healthcare system...
2018: PloS One
Kathleen Mary Noon, Stephen Maxwell Montgomery, Nicholas Edward Adlard, Michel Anton Kroes
OBJECTIVES: Specific economic model types often become de facto standard for health technology appraisal over time. Markov and discrete event simulation (DES) models were compared to investigate the impact of innovative modeling on the cost-effectiveness of disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS). Fingolimod was compared to dimethyl fumarate (DMF; in highly active [HA] RRMS), alemtuzumab (in HA RRMS) and natalizumab (in rapidly evolving severe RRMS)...
July 5, 2018: Journal of Medical Economics
Antonio Nardone, Elena Paola Ferrari
OBJECTIVES: Chronic diseases are a major problem, whose importance is nowadays raising up. Up to 86% of deaths are directly related to chronic diseases in Europe as they represent large amount of total diseases, with a major impact on global health spending. METHODS: Patients suffering from heterogeneous disabilities (such as Parkinson's disease, stroke, multiple sclerosis, osteoporosis, osteoarthritis) often show an interaction between the main disease and comorbidity and multimorbidity...
February 2018: Giornale Italiano di Medicina del Lavoro Ed Ergonomia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"